Clearline Capital LP Sells 22,416 Shares of Heron Therapeutics Inc (NASDAQ:HRTX)

Share on StockTwits

Clearline Capital LP decreased its holdings in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 57.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,920 shares of the biotechnology company’s stock after selling 22,416 shares during the period. Clearline Capital LP’s holdings in Heron Therapeutics were worth $315,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HRTX. Meadow Creek Investment Management LLC bought a new position in Heron Therapeutics during the second quarter worth about $27,000. Lindbrook Capital LLC bought a new position in Heron Therapeutics during the second quarter worth about $37,000. US Bancorp DE lifted its stake in Heron Therapeutics by 75.6% during the second quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,769 shares during the period. Tiverton Asset Management LLC bought a new position in Heron Therapeutics during the second quarter worth about $101,000. Finally, SG Americas Securities LLC bought a new position in Heron Therapeutics during the first quarter worth about $151,000.

HRTX stock traded down $0.29 during trading on Thursday, hitting $20.71. The company had a trading volume of 6,649 shares, compared to its average volume of 634,143. The company has a quick ratio of 3.70, a current ratio of 4.01 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $18.11 and a 200-day moving average price of $20.07. Heron Therapeutics Inc has a 12 month low of $15.68 and a 12 month high of $34.50. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -8.50 and a beta of 1.47.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. The firm had revenue of $36.66 million during the quarter, compared to analysts’ expectations of $31.04 million. Equities analysts expect that Heron Therapeutics Inc will post -2.73 EPS for the current year.

A number of research firms have recently issued reports on HRTX. BidaskClub upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. Evercore ISI reiterated a “buy” rating and issued a $75.00 target price on shares of Heron Therapeutics in a research note on Tuesday, August 13th. Northland Securities reiterated a “buy” rating and issued a $55.00 target price on shares of Heron Therapeutics in a research note on Monday, August 5th. Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 target price on shares of Heron Therapeutics in a research note on Monday, August 5th. Finally, ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $52.67.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Story: Systematic Risk

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.